Cutaneous Leishmaniases
13
1
1
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
23.1%
3 terminated out of 13 trials
72.7%
-13.8% vs benchmark
15%
2 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (13)
Complex Cutaneous Leishmaniasis Healing Study in Algeria
Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World
Spatial Analysis of Host-parasite Interactions in Cutaneous Leishmaniasis in Ethiopia
OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
Cutaneous Leishmaniasis Diagnostic Study
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective Study
Diagnosis of Cutaneous Leishmaniasis Using the CL-detect Rapid Test in Travelers and Migrants in Belgium
Outcomes of Complicated CL in Ethiopia Treated With Miltefosine
Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis
Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan
Evaluation of Point-of-care Tests for the Diagnosis of Cutaneous Leishmaniasis in Afghanistan